Proteomics-based prediction of clinical response in acute myeloid leukemia.
暂无分享,去创建一个
Amber C. Donahue | E. Estey | H. Kantarjian | S. O'brien | F. Giles | M. Albitar | S. Potts | I. Jilani
[1] S. Hanash,et al. Mining the plasma proteome for cancer biomarkers , 2008, Nature.
[2] Gil Alterovitz,et al. Serum proteome profiling detects myelodysplastic syndromes and identifies CXC chemokine ligands 4 and 7 as markers for advanced disease , 2007, Proceedings of the National Academy of Sciences.
[3] F. Grall,et al. Perspectives of proteomics in acute myeloid leukemia , 2006, Expert review of anticancer therapy.
[4] E. Estey,et al. Proteomic‐based prediction of clinical behavior in adult acute lymphoblastic leukemia , 2006, Cancer.
[5] T. Veenstra,et al. Enrichment of low-molecular-weight proteins from biofluids for biomarker discovery , 2005, Expert review of proteomics.
[6] A. Zipursky,et al. Distinct gene signatures of transient and acute megakaryoblastic leukemia in Down syndrome , 2004, Leukemia.
[7] L. Rassenti,et al. Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti‐CD52 antibodies , 2004, Cancer.
[8] J. Wiemer,et al. Bioinformatics in proteomics: application, terminology, and pitfalls. , 2004, Pathology, research and practice.
[9] E. Estey,et al. Relative increase in leukemia-specific DNA in peripheral blood plasma from patients with acute myeloid leukemia and myelodysplasia. , 2004, Blood.
[10] T. Veenstra,et al. The Human Plasma Proteome , 2004, Molecular & Cellular Proteomics.
[11] C. Bloomfield,et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] J. Armitage,et al. Circulating CD20 and CD52 in patients with non‐Hodgkin's lymphoma or Hodgkin's disease , 2003, British journal of haematology.
[13] K. Do,et al. Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. , 2003, Blood.
[14] David E. Misek,et al. Discordant Protein and mRNA Expression in Lung Adenocarcinomas * , 2002, Molecular & Cellular Proteomics.
[15] K Wheatley,et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. , 1998, Blood.
[16] Thomas Deufel,et al. Use of SELDI-TOF mass spectrometry for identification of new biomarkers: potential and limitations. , 2007, Clinical chemistry and laboratory medicine.
[17] E. Estey,et al. Having a higher blast percentage in circulation than bone marrow: clinical implications in myelodysplastic syndrome and acute lymphoid and myeloid leukemias , 2005, Leukemia.
[18] M. Caligiuri,et al. Better detection of FLT3 internal tandem duplication using peripheral blood plasma DNA , 2003, Leukemia.